All in all, our research first reveals the synergistic antileukemic effect between Apatinib and HHT on FLT3-ITD mutant AML cells, likely through inhibiting VEGFR-2-mediated signaling pathways, and suggests potential benefits and clinical application of Apatinib combined with HHT in the treatment of AML patients. Here, KDR is linked to acute myeloid leukemia.